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ABSTRACT
Neuroinflammation has been implicated in the pathogenesis of Alzheimer’s Disease 
(AD) and often characterized by activation of glial cells and the subsequent up- 
regulation of various cytokines. Neuronal damage would then set in and lead to 
deterioration o f cognitive function. Virgin Coconut Oil (VCO) has been reported to 
possess anti-bacterial, anti-viral, anti-oxidants and anti-inflammatory properties. 
Capitalizing on these therapeutic effects, the present study investigated for the first 
time the potential neuroprotective effect o f VCO in vitro and in vivo. For this purpose, 
neuroprotection by VCO against amyloid-|3-(A(3) and Lipopolysaccharide(LPS)- 
induced cell death and Reactive Oxygen Species (ROS) production of SK-N-SH 
(neuroblastoma cells) was assessed. The in vitro findings were validated using normal 
and LPS-induced memory impaired animal models in vivo. A total o f 36 male Wistar 
rats (7-8 weeks) were randomly assigned to 6 gyoups (n=6 /group). The treatment 
groups were administered with 1, 5 and lOmL/kg of VCO for 31 days by oral gavages. 
The cognitive functions of the treated-rats were then assessed using the Morris Water 
Maze Test. Collected brains were homogenised and subjected to biochemical analyses 
o f Acetylcholine (ACh), Acetylcholinesterase (AChE), antioxidative enzymes 
[Superoxide dismutase (SOD), Catalase (CAT), Glutathione (GSH), Glutathione 
peroxidase (GPx) and Glutathione reductase (GRx)], lipid peroxidase 
[Malondialdehyde (MDA)], nitric oxide (NO), cytokines (IL1-/3, IFN-y and IL-10) as 
well as inflammatory (COX-2 and iNOS) and amyloidogenic genes (BACE-1). Next, 
yet another 48 male Wistar rats (7-8 weeks) were assigned for neuroinflammatory 
study. The treatment groups (1, 5 and lOml/kg) were administered with 1, 5 and 
1 OmL/kg o f VCO for 31 days by oral gavage in the presence o f 0.25 mg/kg LPS (i.p.). 
a-Tocopherol (150 mg/kg) was used as positive control throughout the in vivo studies. 
The results showed that 100|ag/mL VCO significantly improved viability of SK-N-SH 
(+47.25%; p<0.01 and 57.46%; p<0.001) and inhibited ROS production (-18.36%; 
p<0.001 and -30.96%; p<0.001) in the presence o f A/3 and LPS respectively. 
Subsequent validation in normal rats indicated that VCO significantly enhanced 
cognitive functions [escape latency (-29.62±1.22%), escape distance (-23.87±0.20%) 
and total time spent on platform (+36.84%; p<0.05)]. The findings were mediated 
through elevation of ACh (+15.39%; pO.OOl), SOD (+8.30%; p<0.05), CAT 
(+67.15%; pO.OOl), GSH (+30.45%; pO.OOl) and GPx (+14.31%; pO.OOl) and 
reduction of AChE (-23.16%; pO.OOl), MDA (-45.14%; pO.OOl) and NO (-65.38%; 
p<0.001). On the other hand, exposure o f LPS-induced memory impaired rats to VCO 
resulted significantly improved cognitive functions [escape latency(-45.87±0.61%), 
escape distance (-32.63+0.24%) and total time spent on platform (+81.82%; pO.O l)]. 
The improvements were mediated through elevation o f ACh (+26.80%; pO.OOl), 
SOD (+8.25%; p<0.05), CAT (+69.50%; pO.OOl), GSH (+99.27%; pO.OOl), GPx 
(+15.10%; pO.OOl), GRx (+26.40%; pO.OOl) and IL-10 (+34.05%; pO .O l) and 
reduction o f AChE (-44.83%; pO.OOl), MDA (-58.73%; pO.OOl), NO (-52.71%; 
pO.OOl), IL-10 (-64.85%; pO.OOl), IFN-y (-25.03%; p 0 .0 5 ), COX-2 (-67.73%; 
pO.OOl), iNOS (-65.63%; pO.OOl) and BACE-1 (-75%; pO.OOl). The present 
findings strongly implied that VCO has neuroprotective effects and has the potential 
to be a memory enhancer. This neuroprotective effect was mediated, at least in part, 
through the inflammatory, cholinergic and amyloidogenic pathways.
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